As consideration for the minority interest, the former minority shareholders has received a cash payment of $1.75 million, convertible notes totaling $1.5 million bearing interest at 8% maturing
This supplement seeks approval to move to a pivotal trial to study the effectiveness in the prevention of contrast-induced nephropathy. PLC expects to commence the pivotal trial after
The Japan agency has granted Japanese good manufacturing practice (GMP) approval, enabling the sale of Criticare Systems’s (CSI) gas technology in the Japanese market. This represents an important
ISS Solutions is also contracted to purchase, install, and test clinical equipment for Geisinger Wyoming Valley’s new Critical Care Tower, a $60 million, 178,000 square foot facility in
Of the 33 patients who were enrolled in the study, four patients had prostate specific antigen (PSA) only disease, 27 patients had bone metastases and three patients had
According to company, this approval of Wellbutrin XL in seasonal major depressive illness represents company’s third notice of compliance in the past six months. Biovail Pharmaceuticals Canada (BPC),
The alliance is expected to bring together the high quality scientific capabilities of Sundia and HD BioSciences with NovaSecta’s extensive client base and unique understanding of European mid-sized
Ten subjects have been recruited for the Phase I trial at four leading ophthalmic centers throughout the US, including Doheny Eye Institute at the University of Southern California
This Phase II study was designed as an open-label, randomized, multicenter study evaluating weekly administration of OGX-011 in combination with second-line chemotherapy. According to data the primary objectives
In vitro, ITI-007 was shown to be a potent, sub-nanomolar, antagonist at 5HT2A receptors with a 60-fold higher affinity for 5HT2A receptors over D2 receptors. In vivo, ITI-007
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.